Beyond Meat Q3 2025 Earnings Slide

Beyond Meat Q3 2025 earnings show widening losses, weaker sales and a delayed 10-Q as law firms probe asset valuations, pressuring near-term trading flow.

November 10, 2025·2 min read
View all news articles
Flat-vector cover showing a fading plant-based burger icon under muted shadow to symbolize Beyond Meat Q3 2025 earnings slide.

KEY TAKEAWAYS

  • Q3 net loss widened to $111M and revenue fell 13.3% to $70M.
  • Adjusted EPS was -$0.47, missing Street by $0.04.
  • Company delayed its 10-Q while finalizing a material non-cash impairment and law firms opened probes.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Beyond Meat (BYND) reported Q3 2025 earnings on Nov. 10, 2025, showing widening losses and weaker sales. The company delayed its 10-Q filing to complete an impairment review, while multiple law firms launched federal securities law investigations into its asset valuations and disclosures.

Earnings Decline and Guidance Miss

Beyond Meat posted a net loss of $110.7 million in Q3 2025, compared with a $26.6 million loss a year earlier, with revenue falling 13.3% year on year to $70.22 million. Adjusted earnings per share were -$0.47, missing consensus by $0.04, while sales volumes declined 10.3% from the prior year.

Profitability and cash flow worsened sharply. Operating margin dropped to -160% from -38.2% in Q3 2024, and free cash flow was negative $41.69 million, nearly double the previous year’s negative $24.07 million. Management attributed the results to continued weak demand and rising costs.

For Q4 2025, Beyond Meat set revenue guidance with a midpoint of $62.5 million, about 11.9% below Street estimates of $70.97 million. The company did not update full-year targets in the release. Its market capitalization stood at $546.1 million as of the report date.

Impairment Review and Federal Investigations

Beyond Meat delayed its Form 10-Q filing to finalize a material non-cash impairment charge related to certain long-lived assets. The company disclosed on Oct. 24 that it expected to record this impairment and postponed its Q3 earnings release on Nov. 3 to complete the review. It filed an 8-K on Nov. 7 announcing the results would be released on Nov. 10, when it also furnished the press release as Exhibit 99.1 to the SEC.

Between Nov. 9 and Nov. 10, multiple law firms, including Bleichmar Fonti & Auld LLP and Portnoy, announced federal securities law investigations into Beyond Meat’s asset valuations and disclosures. The inquiries allege potential overstatement of asset values and question the adequacy of related disclosures. No regulatory enforcement or formal findings have been announced.

The widening losses, declining sales volumes, below-consensus guidance, and ongoing impairment review with related investigations raise near-term scrutiny over Beyond Meat’s financial outlook and valuation.

“Beyond Meat delayed filing its 10-Q for its fiscal quarter ended September 27, 2025,” the company said in its press release.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

U.S.-Switzerland Trade Deal Lowers Tariffs

U.S.-Switzerland trade deal eases pressure on Swiss watch and pharmaceutical exporters and reduces a near-term sales and pricing headwind for traders.

Ron Baron Tesla Sees $2,500 Target, Holds Stakes

Ron Baron Tesla reaffirmed a lifetime hold and backed Musk's pay package, spotlighting governance and focusing investors on his $2,500 Tesla price target.

StubHub Q3 Earnings: Stock Falls After Guidance Withheld

StubHub Q3 earnings showed revenue growth but a large IPO-related net loss and no Q4 guidance, prompting a steep share selloff and pressured positioning.

Lundbeck Bid for Avadel Tops Alkermes Deal

Lundbeck Bid for Avadel raises takeover stakes by topping Alkermes' signed agreement and could force matching or renegotiation that reshapes deal certainty

Merck To Acquire Cidara Therapeutics

Merck to acquire Cidara strengthens its antiviral and respiratory pipeline ahead of Keytruda patent expiry and shifts near-term trader positioning.

Walmart CEO Transition Names John Furner

Walmart CEO transition names John Furner; the board appointment and handover aim to preserve operational continuity and limit governance uncertainty.